Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma

Yan Ding, Elissa A. Boguslawski, Bree D. Berghuis, John J. Young, Zhongfa Zhang, Kim Hardy, Kyle Furge, Eric Kort, Arthur E. Frankel, Rick V. Hay, James H. Resau, Nicholas S. Duesbery

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We hypothesized that signaling through multiple mitogen-activated protein kinase (MAPK) kinase (MKK) pathways is essential for the growth and vascularization of soft-tissue sarcomas, which are malignant tumors derived from mesenchymal tissues. We tested this using HT-1080, NCI, and Shac fibrosarcoma-derived cell lines and anthrax lethal toxin (LeTx), a bacterial toxin that inactivates MKKs. Western blots confirmed that LeTx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 MAPK in vitro. Although short treatments with LeTx only modestly affected cell proliferation, sustained treatment markedly reduced cell numbers. LeTx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor. Similar results were obtained with cell lines derived from malignant fibrous histiocytomas, leiomyosarcomas, and liposarcomas. In vivo, LeTx decreased MAPK activity and blocked fibrosarcoma growth. Growth inhibition correlated with decreased cellular proliferation and extensive necrosis, and it was accompanied by a decrease in tumor mean vessel density as well as a reduction in serum expression of angioproliferative cytokines. Vital imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of LeTx on tumor perfusion were remarkably rapid (<24 h) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues. These results are consistent with our initial hypothesis and lead us to propose that MKK inhibition by LeTx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions.

Original languageEnglish (US)
Pages (from-to)648-658
Number of pages11
JournalMolecular Cancer Therapeutics
Volume7
Issue number3
DOIs
StatePublished - Mar 1 2008

Fingerprint

Fibrosarcoma
Mitogen-Activated Protein Kinase Kinases
Growth
Perfusion
Cell Proliferation
Bacterial Toxins
Microbubbles
Cell Line
Malignant Fibrous Histiocytoma
Liposarcoma
Neoplasms
Leiomyosarcoma
Extracellular Signal-Regulated MAP Kinases
p38 Mitogen-Activated Protein Kinases
Fibroblast Growth Factor 2
Mitogen-Activated Protein Kinases
Interleukin-8
Sarcoma
Vascular Endothelial Growth Factor A
Necrosis

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Ding, Y., Boguslawski, E. A., Berghuis, B. D., Young, J. J., Zhang, Z., Hardy, K., ... Duesbery, N. S. (2008). Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Molecular Cancer Therapeutics, 7(3), 648-658. https://doi.org/10.1158/1535-7163.MCT-07-2229

Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. / Ding, Yan; Boguslawski, Elissa A.; Berghuis, Bree D.; Young, John J.; Zhang, Zhongfa; Hardy, Kim; Furge, Kyle; Kort, Eric; Frankel, Arthur E.; Hay, Rick V.; Resau, James H.; Duesbery, Nicholas S.

In: Molecular Cancer Therapeutics, Vol. 7, No. 3, 01.03.2008, p. 648-658.

Research output: Contribution to journalArticle

Ding, Y, Boguslawski, EA, Berghuis, BD, Young, JJ, Zhang, Z, Hardy, K, Furge, K, Kort, E, Frankel, AE, Hay, RV, Resau, JH & Duesbery, NS 2008, 'Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma', Molecular Cancer Therapeutics, vol. 7, no. 3, pp. 648-658. https://doi.org/10.1158/1535-7163.MCT-07-2229
Ding, Yan ; Boguslawski, Elissa A. ; Berghuis, Bree D. ; Young, John J. ; Zhang, Zhongfa ; Hardy, Kim ; Furge, Kyle ; Kort, Eric ; Frankel, Arthur E. ; Hay, Rick V. ; Resau, James H. ; Duesbery, Nicholas S. / Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. In: Molecular Cancer Therapeutics. 2008 ; Vol. 7, No. 3. pp. 648-658.
@article{cfd8814e20b549d7819271d81e29e44f,
title = "Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma",
abstract = "We hypothesized that signaling through multiple mitogen-activated protein kinase (MAPK) kinase (MKK) pathways is essential for the growth and vascularization of soft-tissue sarcomas, which are malignant tumors derived from mesenchymal tissues. We tested this using HT-1080, NCI, and Shac fibrosarcoma-derived cell lines and anthrax lethal toxin (LeTx), a bacterial toxin that inactivates MKKs. Western blots confirmed that LeTx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 MAPK in vitro. Although short treatments with LeTx only modestly affected cell proliferation, sustained treatment markedly reduced cell numbers. LeTx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor. Similar results were obtained with cell lines derived from malignant fibrous histiocytomas, leiomyosarcomas, and liposarcomas. In vivo, LeTx decreased MAPK activity and blocked fibrosarcoma growth. Growth inhibition correlated with decreased cellular proliferation and extensive necrosis, and it was accompanied by a decrease in tumor mean vessel density as well as a reduction in serum expression of angioproliferative cytokines. Vital imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of LeTx on tumor perfusion were remarkably rapid (<24 h) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues. These results are consistent with our initial hypothesis and lead us to propose that MKK inhibition by LeTx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions.",
author = "Yan Ding and Boguslawski, {Elissa A.} and Berghuis, {Bree D.} and Young, {John J.} and Zhongfa Zhang and Kim Hardy and Kyle Furge and Eric Kort and Frankel, {Arthur E.} and Hay, {Rick V.} and Resau, {James H.} and Duesbery, {Nicholas S.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-07-2229",
language = "English (US)",
volume = "7",
pages = "648--658",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma

AU - Ding, Yan

AU - Boguslawski, Elissa A.

AU - Berghuis, Bree D.

AU - Young, John J.

AU - Zhang, Zhongfa

AU - Hardy, Kim

AU - Furge, Kyle

AU - Kort, Eric

AU - Frankel, Arthur E.

AU - Hay, Rick V.

AU - Resau, James H.

AU - Duesbery, Nicholas S.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - We hypothesized that signaling through multiple mitogen-activated protein kinase (MAPK) kinase (MKK) pathways is essential for the growth and vascularization of soft-tissue sarcomas, which are malignant tumors derived from mesenchymal tissues. We tested this using HT-1080, NCI, and Shac fibrosarcoma-derived cell lines and anthrax lethal toxin (LeTx), a bacterial toxin that inactivates MKKs. Western blots confirmed that LeTx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 MAPK in vitro. Although short treatments with LeTx only modestly affected cell proliferation, sustained treatment markedly reduced cell numbers. LeTx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor. Similar results were obtained with cell lines derived from malignant fibrous histiocytomas, leiomyosarcomas, and liposarcomas. In vivo, LeTx decreased MAPK activity and blocked fibrosarcoma growth. Growth inhibition correlated with decreased cellular proliferation and extensive necrosis, and it was accompanied by a decrease in tumor mean vessel density as well as a reduction in serum expression of angioproliferative cytokines. Vital imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of LeTx on tumor perfusion were remarkably rapid (<24 h) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues. These results are consistent with our initial hypothesis and lead us to propose that MKK inhibition by LeTx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions.

AB - We hypothesized that signaling through multiple mitogen-activated protein kinase (MAPK) kinase (MKK) pathways is essential for the growth and vascularization of soft-tissue sarcomas, which are malignant tumors derived from mesenchymal tissues. We tested this using HT-1080, NCI, and Shac fibrosarcoma-derived cell lines and anthrax lethal toxin (LeTx), a bacterial toxin that inactivates MKKs. Western blots confirmed that LeTx treatment reduced the levels of phosphorylated extracellular signal-regulated kinase and p38 MAPK in vitro. Although short treatments with LeTx only modestly affected cell proliferation, sustained treatment markedly reduced cell numbers. LeTx also substantially inhibited the extracellular release of angioproliferative factors including vascular endothelial growth factor, interleukin-8, and basic fibroblast growth factor. Similar results were obtained with cell lines derived from malignant fibrous histiocytomas, leiomyosarcomas, and liposarcomas. In vivo, LeTx decreased MAPK activity and blocked fibrosarcoma growth. Growth inhibition correlated with decreased cellular proliferation and extensive necrosis, and it was accompanied by a decrease in tumor mean vessel density as well as a reduction in serum expression of angioproliferative cytokines. Vital imaging using high-resolution ultrasound enhanced with contrast microbubbles revealed that the effects of LeTx on tumor perfusion were remarkably rapid (<24 h) and resulted in a marked reduction of perfusion within the tumor but not in nontumor tissues. These results are consistent with our initial hypothesis and lead us to propose that MKK inhibition by LeTx is a broadly effective strategy for targeting neovascularization in fibrosarcomas and other similar proliferative lesions.

UR - http://www.scopus.com/inward/record.url?scp=41649100471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41649100471&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-07-2229

DO - 10.1158/1535-7163.MCT-07-2229

M3 - Article

C2 - 18319331

AN - SCOPUS:41649100471

VL - 7

SP - 648

EP - 658

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -